Galapagos (GLPG) Projected to Post Quarterly Earnings on Wednesday

Galapagos (NASDAQ:GLPG) is projected to release its Q1 2025 earnings data after the market closes on Wednesday, April 23rd. Analysts expect Galapagos to post earnings of ($0.19) per share and revenue of $72.22 million for the quarter.

Galapagos Price Performance

GLPG opened at $24.64 on Tuesday. Galapagos has a one year low of $22.36 and a one year high of $31.23. The stock’s fifty day moving average is $25.37 and its 200-day moving average is $26.27.

Analyst Ratings Changes

Several analysts have issued reports on GLPG shares. TD Cowen downgraded shares of Galapagos from a “strong-buy” rating to a “strong sell” rating in a research note on Thursday, January 9th. Morgan Stanley cut Galapagos from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $31.00 to $22.00 in a research note on Friday, February 14th. Finally, Barclays restated an “underweight” rating on shares of Galapagos in a report on Thursday, January 23rd. Four investment analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. According to MarketBeat.com, Galapagos presently has a consensus rating of “Hold” and a consensus price target of $25.33.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.